Journal of Pediatric Hematology/Oncology · 2008 · 18 citations · 15 references
Life SciencesGeneticsMolecular GeneticsGene ExpressionMedical GeneticsRna ProcessingAlternative SplicingAnemiaGenetic DisordersRed Blood Cell DisordersRna EditingRna SplicingAntisense RnasDisease-associated Splicing DefectsEx Vivo Gene CorrectionHemoglobin LevelsMutationPre-messenger Ribonucleic Acid (Pre-mrna) SplicingSplice-site MutationsSplicing Mutations
The splicing mutation in intron 1 of beta-globin gene (IVS1-110) is the most common mutation in Egyptian thalassemics that causes aberrant splicing of pre-mRNA and deficient beta-globin chain synthesis. Antisense oligonucleotides (ASONs) are compounds that redirect pre-mRNA splicing and modify gene expression. Our aim was ex vivo correction of the aberrant splicing of beta-globin110 pre-mRNA by ASON against the 3' aberrant splice site. Peripheral blood mononuclear cells of 10 thalassemic patients with IVS1-110 mutation were duplicated and 1 was treated with 20 micromoL/mL morpholino ASON targeted against the 3' aberrant splice site. The level of total hemoglobin (Hb), fetal Hb, and mRNA were estimated in the duplicate samples. Five cases (50%) showed correction with ASON treatment, of which 2 cases showed the appearance of corrected mRNA band with absence of the aberrant band and 3 cases showed an increased ratio of the corrected to the aberrant mRNA band from 2:1 to 3:1, and 4:1. The total Hb showed significant increase in the 5 corrected cases. In conclusion, ASON can restore correct splicing of beta-globin pre-mRNA leading to correct gene product in cultured erythropoietic cells. These results suggest the applicability of ASON for the treatment of thalassemia.
15
Hassan Abolghasemi, Ali Amid, Sirous Zeinali et al. · Journal of Pediatric Hematology/Oncology · 2007 · 219 citations
Medicine, Genetics, Hematology +12